Table 1.
Methods | Origin | Other components | Method highlight | Medium | Applications | Ref. |
---|---|---|---|---|---|---|
Patient-derived | Patient tumor | Matrigel forms | Orbital shaking, enzymatic digestion, long-term culture |
EGF, bFGF, no serum | Profiling, spatial structure |
[17] |
Patient-derived | Patient tumor | Agar coating | Mechanically mincing, no enzymatic digestion | 10% FBS, no growth factor |
Profiling, drug screening | [58] |
Patient-derived | Patient tumor | No | Mechanically mincing, no enzymatic digestion, long-term culture orbital shaking, can be bio-banked | No serum or growth factor | Profiling, spatial structure, drug test, CAR-T co-culture |
[15,22] |
Patient-derived | Patient tumor | Matrigel forms | Mechanically mincing, no enzymatic digestion | EGF, bFGF, no serum | Profiling | [62] |
iPSC-derived; fusion | Brain organoids from H9 | No | Electroporation, CRISPR-mediated HR, HRasG12V/TP53 |
Differentiation medium with vitamin A | Invasion | [16] |
iPSC-derived | Brain organoids from H9 | No | Electroporation, CRISPR and transposon, NF1/P53/PTEN triple knockout and others |
Differentiation medium with vitamin A | Invasion, treatment response | [20] |
iPSC-derived | Patient line | No | patient-specific c-met mutation | E8 medium | Treatment response | [19] |
iPSC-derived | Human iPSCs from Domenico Delia |
No | Electroporation, mutant human MET and p53R273C | Cortical differentiation medium | Quiescent cell tracing, treatment response | [63] |
Fusion | Patient-derived GSCs | Cerebral organoids | Orbital shaking, last for up to 14 days | GSC culture media containing EGF and FGF | Invasion, treatment response | [18] |
Fusion | GSCs, GSC spheres | Cerebral organoids | Spinner flask, long-term culture |
GSC culture media containing EGF and FGF | Clearing, time lapse imaging | [94] |
Fusion | GSC lines | Cerebral organoids | Orbital shaking | GSC culture media containing EGF and FGF | Invasion | [95] |
Bio-printing | Human GBM lines | Fibrin bioink, pericytes, astrocytes, microglia, HUVECs |
Perfusable vasculature, different human-sourced cellular components | 10% FBS | Dormancy modeling, vasculature, Cell–cell-interaction, treatment response |
[98] |
Bio-printing | Patient-derived tumor cells | Brain-decellularized ECM, HUVECs | Cancer-stroma concentric-ring structure | 10% FBS | Invasion, microvessels, drug screening |
[23] |
Bio-printing | GSCs | Hyaluronic acid-rich hydrogel, NPCs, astrocytes, macrophages | Different human-sourced cellular components | GSC culture media containing EGF and FGF | Drug sensitivity, cellular crosstalk, invasion | [100] |
Bio-printing | Spheroids from U87 | Collagen hydrogel | Microfluidic devices | 10% FBS | Migration, drug evaluation | [24] |
Bio-printing | Spheroids from tumor specimen | Fibrin hydrogel, HUVECs | Fibrin scaffold | 10% FBS | Migration, cellular crosstalk | [101] |
Bio-printing | Spheroids from glioma PDX lines | Fibrin, pericytes, astrocytes, endothelial cells | Microfluidic devices, different human-sourced cellular components | PDX culture media | BBB penetration assessment | [99] |